tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
PremiumThe FlyWedbush sees no threat to Ascendis’ Yorvipath from competitor data
21d ago
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
Premium
Ratings
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
21d ago
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
Premium
Ratings
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
21d ago
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
PremiumRatingsAscendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
1M ago
Ascendis Pharma price target raised to $260 from $254 at JPMorgan
Premium
The Fly
Ascendis Pharma price target raised to $260 from $254 at JPMorgan
2M ago
Ascendis Pharma Grants Employee Warrants to Foster Growth
Premium
Company Announcements
Ascendis Pharma Grants Employee Warrants to Foster Growth
2M ago
Ascendis Pharma price target raised to $307 from $306 at UBS
PremiumThe FlyAscendis Pharma price target raised to $307 from $306 at UBS
2M ago
Ascendis Pharma price target raised to $290 from $243 at Citi
Premium
The Fly
Ascendis Pharma price target raised to $290 from $243 at Citi
2M ago
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
Premium
The Fly
Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100